Article: Researchers Point to Germany’s Model for Purchasing Cancer Drugs

July 13, 2020

Researchers say U.S. policymakers should look to Germany’s drug purchasing model to try and better align cancer drug prices with their clinical benefits, according to a STAT Pharmalot article.

According to the article, Germany’s model ultimately led to a 25 percent drop in prices one year post-launch.

The researchers’ recommendation came on the heels of an analysis involving 57 cancer drugs launched in Germany between 2002-2017.

To read the full article on STAT, click here. (Paid subscription required)

Share This Story!